Access

Insight

Nature 450, 1001-1009 (13 December 2007) | doi:10.1038/nature06526; Published online 12 December 2007

Open Innovation Challenges

naturejobs

More science jobs
Post a job for free

Review Article Reaching for high-hanging fruit in drug discovery at protein–protein interfaces

James A. Wells1,2 & Christopher L. McClendon3

Top

Targeting the interfaces between proteins has huge therapeutic potential, but discovering small-molecule drugs that disrupt protein–protein interactions is an enormous challenge. Several recent success stories, however, indicate that protein–protein interfaces might be more tractable than has been thought. These studies discovered small molecules that bind with drug-like potencies to 'hotspots' on the contact surfaces involved in protein–protein interactions. Remarkably, these small molecules bind deeper within the contact surface of the target protein, and bind with much higher efficiencies, than do the contact atoms of the natural protein partner. Some of these small molecules are now making their way through clinical trials, so this high-hanging fruit might not be far out of reach.

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

Ending the prolonged life of cancer cells

Nature Chemical Biology News and Views (01 Jun 2005)

Death by design: the big debut of small molecules

Nature Cell Biology News and Views (01 Feb 2001)